Genocea to Participate in the B. Riley Securities’ Virtual Oncology Investor Conference
Genocea Biosciences (NASDAQ: GNCA) will have its CEO, Chip Clark, participate in a fireside chat at the B. Riley Securities’ Virtual Oncology Investor Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genocea Biosciences (NASDAQ: GNCA) will have its CEO, Chip Clark, participate in a fireside chat at the B. Riley Securities’ Virtual Oncology Investor Conference. This event is scheduled for January 21, 2021, from 11:00 am to 11:30 am ET. Investors can access the live webcast on Genocea's website, where it will also be archived for approximately 90 days. Genocea focuses on developing personalized cancer immunotherapies using its ATLAS™ platform to optimize neoantigens and exclude immunosuppressive Inhibigens™.
Details
News Market Reaction – GNCA
The recorded move for GNCA in the trading session of this news was +16.85%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, president and chief executive officer, will participate in a fireside chat at B. Riley Securities’ Virtual Oncology Investor Conference on January 21, 2021 from 11:00 am – 11:30 am Eastern Time. A live webcast of the fireside chat will be available on the Genocea website at http://ir.genocea.com. This event will also remain archived on the Genocea website for approximately 90 days.
About Genocea Biosciences, Inc.
Genocea’s mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient’s T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood. To learn more, please visit www.genocea.com.
Investor Contact:
Dan Ferry
617-430-7576
daniel@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.